Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference



    CALGARY, Oct. 2 /CNW/ - Dr. Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:   ONCY), will present a corporate
overview of the Company at the Maxim Group Growth Conference at 2:30 p.m. ET
on Tuesday, October 7, 2008. The event is being held at the Grand Hyatt Hotel
in New York.
    A live audio link to the webcast presentation is available at
http://www.wsw.com/webcast/maxim/oncy/ on the company's website at
www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes
in advance of the presentation to register and download any necessary
software.
    An audio replay will be accessible on the Oncolytics website following
the presentation.

    About Oncolytics Biotech Inc.

    Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of Phase I/II and Phase II human trials
using REOLYSIN(R), its proprietary formulation of the human reovirus, alone
and in combination with radiation or chemotherapy. For further information
about Oncolytics, please visit www.oncolyticsbiotech.com

    About the Maxim Group Growth Conference

    The Maxim Group Growth Conference will feature interactive presentations
from over 80 companies, as well as one-on-one meetings with executives from
the healthcare, technology, shipping/transportation and emerging growth
sectors. Attendees will include securities analysts, fund managers and
institutional investors.

    The presentation time is subject to change. This release and the
presentation related thereto contain forward-looking statements which involve
known and unknown risks, delays, uncertainties and other factors not under the
Company's control and which may cause actual results, performance or
achievements of the Company to be materially different from the results,
performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as
a cancer treatment, the success and timely completion of clinical studies and
trials, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except
as required by applicable laws.

    %SEDAR: 00013081E




For further information:

For further information: For Canada: Oncolytics Biotech Inc., Cathy
Ward, 210 1167 Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403)
670-7377, Fax: (403) 283-0858, cathy.ward@oncolytics.ca; For Canada: The
Equicom Group, Nick Hurst, 325-300 5th Ave. SW, Calgary, Alberta, T2P 3C4,
Tel: (403) 538-4845, Fax: (403) 237-6916, nhurst@equicomgroup.com; For United
States: The Investor Relations Group, Erika Moran, 11 Stone St, 3rd Floor, New
York, NY, 10004, Tel: (212) 825-3210, Fax: (212) 825-3229,
emoran@investorrelationsgroup.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890